AXSM Nasdaq 2019 - 10 - 16

Axsome Therapeutics, Inc.

AXSM | $71.82 -1.72% 43K

(0.0% 1d) (-5.5% 1m) (2.6% 1y) (0.0% 2d) (2.8% 3d) (11.2% 7d) (40.95% volume)
Earnings Calendar: 2024-02-20
Market Cap: $ 3,402,427,612
http://www.axsome.com
Sec Filling | Patents | 45 employees

(US) Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

nervous system

add to watch list Paper trade email alert is off

Press-releases

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
AXSM | $71.82 -1.72% 43K

Health Technology

| 2.74% | O: -3.37% H: 0.83% C: -0.76%
neurology meeting therapeutics

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
AXSM | $71.82 -1.72% 43K

Health Technology

| 0.61% | O: -2.66% H: 1.26% C: 0.37%
first report therapeutics financial results

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Published: 2024-04-01 (Crawled : 11:00) - globenewswire.com
AXSM | $71.82 -1.72% 43K

Health Technology

| -8.13% | O: 0.32% H: 0.0% C: -3.52%
treatment trial therapeutics solriamfetol

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
AXSM | $71.82 -1.72% 43K

Health Technology

| -9.4% | O: 3.64% H: 0.35% C: -7.48%
narcolepsy therapeutics results

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
AXSM | $71.82 -1.72% 43K

Health Technology

| -9.4% | O: 3.64% H: 0.35% C: -7.48%
axs-12 narcolepsy symphony trial therapeutics

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Published: 2024-03-19 (Crawled : 11:00) - globenewswire.com
AXSM | $71.82 -1.72% 43K

Health Technology

| 0.74% | O: 0.84% H: 5.95% C: 5.09%
treatment trial therapeutics solriamfetol

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Published: 2024-03-05 (Crawled : 12:00) - globenewswire.com
AXSM | $71.82 -1.72% 43K

Health Technology

| -6.55% | O: -0.45% H: 0.86% C: -1.58%
conference biopharma global therapeutics

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Published: 2024-02-27 (Crawled : 12:00) - globenewswire.com
AXSM | $71.82 -1.72% 43K

Health Technology

| -11.2% | O: 0.75% H: 2.12% C: 1.3%
conference therapeutics

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-02-20 (Crawled : 12:00) - globenewswire.com
AXSM | $71.82 -1.72% 43K

Health Technology

| -21.26% | O: -8.42% H: 3.52% C: -4.54%
business year update therapeutics financial results

Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20
Published: 2024-01-23 (Crawled : 12:00) - globenewswire.com
AXSM | $71.82 -1.72% 43K

Health Technology

| -19.62% | O: 0.62% H: 0.43% C: -2.14%
report year therapeutics financial results

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950170-24-039617	4	2024-04-01	2024-04-01	Sell	M	24662	0
0000950170-24-039617	4	2024-04-01	2024-04-01	Sell	S	24662	0
0000950170-24-039617	4	2024-04-01	2024-04-01	Buy	M	24662	24662